Skin of Color Update (SOCU) 2023

Patient race and specific atopic dermatitis diagnoses are associated with differences in dupilumab prescription patterns. Atopic dermatitis (AD) is a common chronic inflammatory disease. Treatment with a systemic immunomodulating agent is indicated in moderate-to-severe AD. These systemic agents include cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, and systemic steroids. Dupilumab, a fully human monoclonal antibody, may be...

Atopic dermatitis severity and treatment patterns do not differ among diverse racial and ethnic groups in the United States, according to a recent study. Atopic dermatitis (AD) has heterogeneous manifestations across regional and racial groups. Previous studies in the United States found racial and ethnic differences in AD disease patterns, including risk factors for severity,...

Air pollutants such as nitrogen dioxide (NO2), carbon monoxide (CO), sulfur dioxide (SO2), and ozone (O3) are linked to the prevalence and severity of atopic dermatitis. These contaminants have been linked to an increased risk of AD during pregnancy, childhood, and maturity. Atopic dermatitis (AD) is a chronic, inflammatory skin disease affecting approximately 20% of...

An Americas Health Foundation panel agreed on the significant prevalence of health disparities related to atopic dermatitis in Latin America. They identified the factors contributing to these disparities and developed expert recommendations. Atopic Dermatitis (AD) is a chronic, heterogeneous skin disease. The condition has multiple risk factors, including genetics, environmental factors, immunological factors, and more....

Struggling with eczema that just won’t quit, especially on your face and neck? A recent study highlights the potential benefits of upadacitinib, a medication that could be an effective option for those hard-to-treat areas. In the study, participants reported improvements in the severity of their symptoms and their overall quality of life. No participants reported...

Has your doctor recommended dupilumab for your child with atopic dermatitis, but you’re unsure about the long-term benefits and safety? A recent study provides some promising answers for this treatment for moderate-to-severe atopic dermatitis. Dupilumab has been shown to provide rapid relief of severe eczema symptoms. The medication has a good safety profile with only...

Medically reviewed by Dr. Shani Saks, D.O. on Sept. 12, 2023 The pathogenesis of stress-induced alopecia areata involves apoptotic and autoimmune pathways that may interact with one another in the development of the disease, serving as potential therapeutic targets. Alopecia areata is an autoimmune dermatological condition that leads to reversible hair loss in the form of patches....

Medically reviewed by Dr. Shani Saks, D.O. on Sept. 10, 2023 Oral Janus kinase inhibitors such as brepocitinib, baricitinib, deuruxolitinib, and ritlecitinib are effective for the treatment of alopecia areata, causing significant regrowth of hair with only mild to moderate adverse effects. Alopecia areata is characterized by the immune-mediated loss of hair in non-cicatricial patches. While...

Medically reviewed by Dr. Shani Saks, D.O. on Sept. 12, 2023 People with alopecia areata have gender-specific comorbidities, including anxiety, dermatitis, hypothyroidism, and hyperlipidemia. According to a recent study, interactions between gender, age, and the severity of the disease influence the onset of these associated diseases. Alopecia areata (AA) is a chronic inflammatory condition considered the second...